Press release
Overactive Bladder Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Astellas Pharma Inc., Laborie, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Overactive Bladder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
• Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
• Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
• In April 2024, SpineX has completed patient enrollment for its CONTINENCE clinical trial (NCT05301335), which evaluates the Scone neuromodulation device for treating neurogenic bladder, often associated with conditions like multiple sclerosis (MS), stroke, or spinal cord injury. Conducted at multiple sites across the U.S., Canada, and India, the study targets adults experiencing overactive bladder symptoms due to these neurological conditions. Researchers at SpineX are optimistic that participants in the trial will experience notable enhancements in self-reported symptoms linked to neurogenic bladder.
• In November 2023, Avation Medical has disclosed encouraging outcomes from the multi-center trial of Vivally, its medical device aimed at addressing overactive bladder (OAB) syndrome. The FREEOAB multi-center study involved 96 OAB patients. Findings indicated notable decreases in daily void, incontinence, and urgency episodes at the 12-week mark, leading to an improved quality of life. Furthermore, these favorable effects endured over the long term, with ongoing enhancements in diary parameters noted at the 12-month follow-up.
Overactive Bladder Overview
Overactive bladder (OAB) is a urinary condition characterized by a frequent and sudden urge to urinate that may be difficult to control. People with OAB often experience urinary urgency, which can lead to involuntary leakage of urine (urge incontinence). This condition can significantly impact daily life and quality of life.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
• ARD-380: Aardvark Therapeutics
• URB937: Exxel Pharma
• Botulax: Hugel
• IMB-115: Imbrium Therapeutics
• TAC-302: Taiho Pharmaceutical
• URO-902: Sumitovant Biopharma
• DA-8010: Dong-A ST
Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
• Overactive Bladder Assessment by Product Type
• Overactive Bladder By Stage and Product Type
• Overactive Bladder Assessment by Route of Administration
• Overactive Bladder By Stage and Route of Administration
• Overactive Bladder Assessment by Molecule Type
• Overactive Bladder by Stage and Molecule Type
DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Overactive Bladder Pipeline Market Drivers
• Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
• However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
• Coverage: Global
• Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
• Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
• Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
• Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Overactive Bladder Market https://www.delveinsight.com/report-store/overactive-bladder-oab-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Overactive Bladder Epidemiology https://www.delveinsight.com/report-store/overactive-bladder-oab-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Overactive Bladder Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Astellas Pharma Inc., Laborie, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma here
News-ID: 3564734 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Overactive
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Top Factor Driving Overactive Bladder Treatment Market Growth in 2025: Geriatric …
What industry-specific factors are fueling the growth of the overactive bladder treatment market?
The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
Overactive Bladder Market Report, History and Forecast 2022-2030
Overactive Bladder Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Overactive Bladder industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, …
Market Analysis and Insights of Overactive Bladder Treatment Market
During the forecasted period of 2023-2032, the market for treatments for overactive bladder will grow at a CAGR of about 4.00%. The main drivers of the overactive bladder treatment market's expansion are the rising prevalence of kidney-related disorders, increased emphasis on medical device research and development expertise and the adoption of cutting-edge IT healthcare technologies, an increasing geriatric population worldwide, and rising…